longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Lakewood-Amedex Biotherapeutics

LABT

1.6708.49% ( -0.155 )
Closed: Sep 25, 16:00:00 (EDT)
Start trading
OverviewOverviewOptionsOptionsNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

About

Lakewood-Amedex Biotherapeutics
Lakewood-Amedex Biotherapeutics
LABT.US

Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial.

Profile

Company Name
Lakewood-Amedex Biotherapeutics, Inc.
Market
NasdaqCM
Founded
2006
Industry
--
Fiscal Year End
December 31
Website
lakewoodamedex.com